Treatment of prostate cancer cells with FK506, which binds to the FK1 domain of FKBPs, or with MJC13, an inhibitor of FKBP52‐AR signaling, also inhibited AR dimer formation. This evidence concerns the gene FKBP4 and prostate cancer.